Research
The ALS Network presented four researchers with the Barber Research Award during the UC ALS Reinvigorating Innovation in ALS Research workshop on May 15-16. From left to right: Julie Smeyers,…
Left to Right: Sheri Strahl, MPH, MBA, President and CEO, ALS Network; Christopher J. McDermott, MBChB, FRCP, PhD, University of Sheffield; Neil A. Shneider, MD, PhD, Columbia University; Jim Essey,…
A groundbreaking experimental therapy for a rare, aggressive form of ALS caused by FUS gene mutations has produced surprising clinical improvements in some patients, including restored mobility and extended survival.…
MaaT033, an oral therapy aiming to restore balance to the collection of bacteria and other microbes in the gut, was safe and well tolerated after three months and showed signs…
With no single known cause, no definitive diagnostic test and no cure, ALS remains a tragically confounding neurodegenerative disease. Its progression varies dramatically from patient to patient, leaving clinicians and…
A neurosurgeon and his team from the University of California (UC) Davis Health have won The Herbert Pardes Clinical Research Excellence Award — given by the nonprofit Clinical Research Forum — for…
The first patient has been dosed in a Phase 1 clinical study testing AMX0114, an experimental therapy being developed by Almylyx Pharmaceuticals for amyotrophic lateral sclerosis (ALS). The treatment targets calpain-2, a protein believed to…
A single dose of Insmed’s investigational gene therapy INS1202 preserved motor function and prolonged survival in a mouse model of amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations. The therapy was also found to…
The ALS Network, in partnership with ALS United, proudly announces that letters of intent for ALS research funding will be accepted April 15 – May 15, 2025. “We are honored…
JERSEY CITY, N.J. March 12, 2025 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025…